Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Geranium Inhalation Aromatherapy for Reducing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy [NA]
A completed clinical trial evaluated whether geranium inhalation aromatherapy reduces nausea and vomiting in cancer patients receiving chemo…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Management of Nausea and Vomiting Chemotherapy-induced in Normandy
This update reports the completion of a clinical trial evaluating strategies to manage chemotherapy-induced nausea and vomiting in patients …
-
FDA approval · 2025-11-24FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for ondansetron from Rising Pharma Holdings, Inc., under the existing ANDA.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting [Phase 2]
Phase 2 clinical trial update for nano-crystalline megestrol acetate aimed at preventing chemotherapy-induced nausea and vomiting; the study…
-
FDA approval · 2025-11-18FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for ondansetron filed by Hospira, approving modifications to an already approved product under an AN…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-11-18FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA granted Hospira, Inc. a supplemental approval for ondansetron (ONDANSETRON) under an ANDA.
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. [Phase 3]
A Phase 3 clinical trial evaluating QLM2010 for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy …
-
FDA approval · 2025-11-17FDA Approved: ONDANSETRON — Supplemental Application (JVET PHARMACEUTICALS LLC)
FDA approved a supplemental application for ondansetron from JVET Pharmaceuticals LLC under an ANDA (generic). The approval covers the use o…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron [Phase 4]
A Phase 4 trial comparing a transdermal granisetron patch to ondansetron for chemotherapy-induced nausea and vomiting is currently recruitin…
-
EMA approval · 2025-11-05EMA Authorised: Ivemend (fosaprepitant) — Merck Sharp & Dohme B.V.
EMA authorised Ivemend (fosaprepitant) by Merck Sharp & Dohme B.V. for prevention of chemotherapy-induced vomiting in cancer patients.
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting [Phase 4]
Phase 4 clinical trial comparing olanzapine-based steroid-sparing therapy to dexamethasone-based therapy for chemotherapy-induced nausea and…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) [Phase 4]
Phase 4 trial (MyRisk) comparing oral Akynzeo to standard of care for preventing chemotherapy-induced nausea and vomiting in high-risk MEC p…
-
FDA approval · 2025-10-23FDA Approved: ONDANSETRON — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for ondansetron hydrochloride (ONDANSETRON) by NorthStar Rx LLC under ANDA078776. This confirms appr…
-
CLINICAL_TRIALS research · 2025-10-08Clinical Trial Update: RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy [Phase 2]
A Phase 2 randomized trial is evaluating olanzapine to prevent chemotherapy-induced nausea and vomiting in children receiving highly emetoge…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting [NA]
A clinical trial evaluating auricular neurostimulation for chemotherapy-induced nausea and vomiting was terminated.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting [NA]
This clinical trial explores whether guided imagery can reduce chemotherapy-related nausea and vomiting in pediatric cancer patients and is …
-
FDA approval · 2025-09-17FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for ondansetron under ANDA078127 held by PAI Holdings (PAI Pharma), authorizing an amendment to the …
-
FDA approval · 2025-09-16FDA Approved: ONDANSETRON — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for ondansetron from Qilu Pharmaceutical Co., Ltd. under ANDA203711.
-
FDA approval · 2025-09-15FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for ondansetron hydrochloride from Hikma Pharmaceuticals USA Inc.
-
FDA approval · 2025-09-09FDA Approved: ONDANSETRON — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's supplemental application for ondansetron, resulting in an approval update to its existing product labeling/indic…
-
FDA approval · 2025-09-09FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)
The FDA approved a supplemental application for ondansetron by AvKARE, enabling continued use of this generic antiemetic product.
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: The Impact of Oral Cryotherapy and Chewing Gum Interventions [NA]
A completed clinical trial evaluating oral cryotherapy and chewing gum interventions for breast cancer patients undergoing chemotherapy, aim…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy [Phase 1]
A Phase 1 trial to evaluate the safety and potential efficacy of Megestrol Acetate in preventing nausea and vomiting caused by highly emetog…
-
FDA approval · 2025-07-21FDA Approved: FOSAPREPITANT — Supplemental Application (Dr. Reddy's Laboratories Inc.,)
FDA approved a supplemental application for fosaprepitant submitted by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2025-07-03FDA Approved: APREPITANT — Supplemental Application (BluePoint Laboratories)
The FDA approved BluePoint Laboratories' supplemental application for aprepitant (ANDA 207777), allowing a generic version of this antiemeti…